Supplementary Methods 1 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer

2026 Open access

Read full text
Authors: Franziska Siegel, Stephan Siegel, Kristýna Kotýnková, Gizem Karsli Uzunbas, Daniel Korr, Haruna Tomono, Sawyer Andersen, D.R. Denney, Markus Berger, Volker Schulze, Timothy A. Lewis, Bethany Kaplan
+14 more Sven Golfier, Jérémie Mortier, Roman Christian Hillig, Ulf Boemer, Kirstin Petersen, Knut Eis, Sybil M. Genther Williams, Dominik Rüttinger, Andrew D. Cherniack, Herbert H. Loong, Koichi Goto, Paolo Grassi, Matthew Meyerson, Heidi E. Greulich
DOI: 10.1158/2159-8290.31047094
Cited by: 1

Abstract

Supplementary Methods: Crystal Structure Determination of Wild-Type EGFR in Complex with Sevabertinib. Xenograft models

Fields of Study & Subjects

Lung Cancer Treatments and Mutations HER2/EGFR in Cancer Research Fibroblast Growth Factor Research

Publication details

Publisher
American Association for Cancer Research (AACR)
Publication date
12 January 2026